In silico investigation of PARP-1 catalytic domains in holo and apo states for the design of high-affinity PARP-1 inhibitors

References

• Amé JC, Spenlehauer C, De Murcia G. The PARP superfamily. BioEssays 2004;26:882–93
   PubMed Web of Science ®Google Scholar
• Kim MY, Zhang T, Kraus WL. Poly(ADP-ribosyl)ation by PARP-1: “PAR-laying” NAD+ into a nuclear signal. Genes Dev 2005;19:1951–67
   PubMed Web of Science ®Google Scholar
• D’Amours D, Desnoyers S, D’Silva I, Poirier GG. Poly(ADP-ribosyl)ation reactions in the regulation of nuclear functions. Biochem J 1999;342:249–68
   PubMed Web of Science ®Google Scholar
• Kraus WL, Lis JT. PARP goes transcription. Cell 2003;113:677–83
   PubMed Web of Science ®Google Scholar
• Griffin RJ, Curtin NJ, Newell DR, et al. The role of inhibitors of poly(ADP-ribose) polymerase as resistance-modifying agents in cancer therapy. Biochimie 1995;77:408–22
   PubMed Web of Science ®Google Scholar
• Bai P, Cantó C. The role of PARP-1 and PARP-2 enzymes in metabolic regulation and disease. Cell Metab 2012;16:290–5
   PubMed Web of Science ®Google Scholar
• Gibson B, Kraus WL. New insights into the molecular and cellular functions of poly(ADP-ribose) and PARPs. Nat Rev Mol cell Biol 2012;13:411–24
   PubMed Web of Science ®Google Scholar
• Soldani C, Scovassi AI. Poly(ADP-ribose) polymerase-1 cleavage during apoptosis: an update. Apoptosis 2002;7:321–8
   PubMed Web of Science ®Google Scholar
• De la Lastra CA, Villegas I, Sánchez-Fidalgo S. Poly(ADP-ribose) polymerase inhibitors: new pharmacological functions and potential clinical implications. Curr Pharm Des 2007;13:933–62
   PubMed Web of Science ®Google Scholar
• Rios J, Puhalla S. PARP inhibitors in breast cancer: BRCA and beyond. Oncology (Williston Park) 2011;25:1014–25
   PubMed Web of Science ®Google Scholar
• Ye N, Chen CH, Chen T, et al. Design, synthesis, and biological evaluation of a series of benzo[de][1,7]naphthyridin-7(8 H)-ones bearing a functionalized longer chain appendage as novel PARP1 inhibitors. J Med Chem 2013;56:2885–903
   PubMed Web of Science ®Google Scholar
• Durdagi S, Deshpande S, Duff HJ, Noskov SY. Modeling of open, closed, and open-inactivated states of the hERG1 channel: structural mechanisms of the state-dependent drug binding. J Chem Inf Model 2012;52:2760–74
   PubMed Web of Science ®Google Scholar
• Subbotina J, Yarov-Yarovoy V, Lees-Miller J, et al. Structural refinement of the hERG1 pore and voltage-sensing domains with ROSETTA-membrane and molecular dynamics simulations. Proteins Struct Funct Bioinf 2010;78:2922–34
   PubMed Web of Science ®Google Scholar
• Mavromoustakos T, Durdagi S, Koukoulitsa C, et al. Strategies in the rational drug design. Curr Med Chem 2011;18:2517–30
   PubMed Web of Science ®Google Scholar
• Durdagi S, Subbotina J, Lees-Miller J, et al. Insights into the molecular mechanism of hERG1 channel activation and blockade by drugs. Curr Med Chem 2010;17:3514–32
   PubMed Web of Science ®Google Scholar
• Durdagi S, Zhao C, Cuervo JE, Noskov SY. Atomistic models for free energy evaluation of drug binding to membrane proteins. Curr Med Chem 2011;18:2601–11
   PubMed Web of Science ®Google Scholar
• Durdagi S, Guo J, Lees-Miller JP, et al. Structure-guided topographic mapping and mutagenesis to elucidate binding sites for the human ether-a-go-go-related gene 1 potassium channel (KCNH2) activator NS1643. J Pharmacol Exp Ther 2012;342:441–52
   PubMed Web of Science ®Google Scholar
• Buturak B, Durdagi S, Noskov SY, Ildeniz, TO. Designing of multi-targeted molecules using combination of molecular screening and in silico drug cardiotoxicity prediction approaches. J Mol Graph Model 2014;50:16–34
   PubMed Web of Science ®Google Scholar
• Guo J, Durdagi S, Changalov M, et al. Structure driven design of novel human ether-a-go-go-related-gene channel (hERG1) activators. PLoS One 2014;9:e105553
   PubMed Web of Science ®Google Scholar
• Madhavi Sastry G, Adzhigirey M, Day T, et al. Protein and ligand preparation: parameters, protocols, and influence on virtual screening enrichments. J Comput Aided Mol Des 2013;27:221–34
   PubMed Web of Science ®Google Scholar
• Li H, Robertson AD, Jensen JH. Very fast empirical prediction and rationalization of protein pK a values. Proteins Struct Funct Genet 2005;61:704–21
   PubMed Web of Science ®Google Scholar
• Humphrey W, Dalke A, Schulten K. VMD: Visual molecular dynamics. J Mol Graph 1996;14:33–8
   PubMed Web of Science ®Google Scholar
• Guvench O, Mallajosyula SS, Raman EP, et al. CHARMM additive all-atom force field for carbohydrate derivatives and its utility in polysaccharide and carbohydrate–protein modeling. J Chem Theory Comput 2011;7:3162–80
   PubMed Web of Science ®Google Scholar
• Nelson MT, Humphrey W, Gursoy A, et al. NAMD: a parallel, object oriented molecular dynamics program. Int J Supercomput Appl High Perform Comput 1996;10:251–68
   Web of Science ®Google Scholar
• Miyamoto S, Kollman PA. SETTLE: an analytical version of the SHAKE and RATTLE algorithm for rigid water models. J Comput Chem 1992;13:952–62
   Web of Science ®Google Scholar
• Rother K. Introduction to PyMOL. Methods Mol Biol Clift NJ 2005;635:0–32
   Google Scholar
• Grant BJ, Rodrigues APC, ElSawy KM, et al. Bio3d: an R package for the comparative analysis of protein structures. Bioinformatics 2006;22:2695–6
   PubMed Web of Science ®Google Scholar
• Pearson K. LIII. On lines and planes of closest fit to systems of points in space. London, Edinburgh, Dublin Philos Mag J Sci 1901;2:559–72
   Google Scholar
• Wishart DS. DrugBank and its relevance to pharmacogenomics. Pharmacogenomics 2008;9:1155–62
   PubMed Web of Science ®Google Scholar
• Chen IJ, Foloppe N. Drug-like bioactive structures and conformational coverage with the ligprep/confgen suite: comparison to programs MOE and catalyst. J Chem Inf Model 2010;50:822–39
   PubMed Web of Science ®Google Scholar
• Maestro, Version 9.2. New York: Schrödinger, LLC; 2011
   Google Scholar
• Halgren TA, Murphy RB, Friesner RA, et al. Glide: a new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening. J Med Chem 2004;47:1750–9
   PubMed Web of Science ®Google Scholar
• Farid R, Day T, Friesner RA, Pearlstein RA. New insights about HERG blockade obtained from protein modeling, potential energy mapping, and docking studies. Bioorganic Med Chem 2006;14:3160–73
   PubMed Web of Science ®Google Scholar
• Jacobson MP, Pincus DL, Rapp CS, et al. A hierarchical approach to all-atom protein loop prediction. Proteins Struct Funct Genet 2004;55:351–67
   PubMed Web of Science ®Google Scholar
• Chen J, Peng H, He J, et al. Synthesis of isoquinolinone-based tricycles as novel poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors. Bioorganic Med Chem Lett 2014;24:2669–73
   PubMed Web of Science ®Google Scholar
• Ferraris DV. Evolution of poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors: from concept to clinic. J Med Chem 2010;31:4561–84
   Google Scholar
• Morrison AR, Moss J, Stevens LA, et al. ART2, a T cell surface mono-ADP-ribosyltransferase, generates extracellular poly(ADP-ribose). J Biol Chem 2006;281:33363–72
   PubMed Web of Science ®Google Scholar
• Hara N, Tsuchiya M, Shimoyama M. Glutamic acid 207 in rodent T-cell RT6 antigens is essential for arginine-specific ADP-ribosylation. J Biol Chem 1996;271:29552–5
   PubMed Web of Science ®Google Scholar
• Ruf A, Rolli V, de Murcia G, Schulz GE. The mechanism of the elongation and branching reaction of poly(ADP-ribose) polymerase as derived from crystal structures and mutagenesis. J Mol Biol 1998;278:57–65
   PubMed Web of Science ®Google Scholar
• Ruf A, Mennissier de Murcia J, de Murcia G, Schulz GE. Structure of the catalytic fragment of poly(AD-ribose) polymerase from chicken. Proc Natl Acad Sci USA 1996;93:7481–5
   PubMed Web of Science ®Google Scholar
• Hannigan K, Kulkarni SS, Bdzhola VG, et al. Identification of novel PARP-1 inhibitors by structure-based virtual screening. Bioorganic Med Chem Lett 2013;23:5790–4
   PubMed Web of Science ®Google Scholar
• Shenkin PS, Mcdonald DQ. Cluster analysis of molecular conformations. J Comput Chem 1994;15:899–916
   Web of Science ®Google Scholar
• Mauser H, Guba W. Recent developments in de novo design and scaffold hopping. Curr Opin Drug Discov Devel 2008;11:365–74
   PubMed Web of Science ®Google Scholar
• Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 2012;64:4–17
   Web of Science ®Google Scholar
• Costantino G, Macchiarulo A, Camaioni E, Pellicciari R. Modeling of poly(ADP-ribose)polymerase (PARP) inhibitors. Docking of ligands and quantitative structure-activity relationship analysis. J Med Chem 2001;44:3786–94
   PubMed Web of Science ®Google Scholar
• Li JH, Serdyuk L, Ferraris DV, et al. Synthesis of substituted 5[H]phenanthridin-6-ones as potent poly(ADP-ribose)polymerase-1 (PARP1) inhibitors. Bioorganic Med Chem Lett 2001;11:1687–90
   PubMed Web of Science ®Google Scholar
• Steinhagen H, Gerisch M, Mittendorf J, et al. Substituted uracil derivatives as potent inhibitors of poly(ADP-ribose)polymerase-1 (PARP-1). Bioorganic Med Chem Lett 2002;12:3187–90
   PubMed Web of Science ®Google Scholar
• Lehtiö L, Jemth AS, Collins R, et al. Structural basis for inhibitor specificity in human poly(ADP-ribose) polymerase-3. J Med Chem 2009;52:3108–11
   PubMed Web of Science ®Google Scholar
• Jagtap PG, Baloglu E, Southan GJ, et al. Discovery of potent poly(ADP-ribose) polymerase-1 inhibitors from the modification of indeno[1,2-c]isoquinolinone. J Med Chem 2005;48:5100–3
   PubMed Web of Science ®Google Scholar
• Jones P, Altamura S, Boueres J, et al. Discovery of 2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide (MK-4827): a novel oral poly(ADP-ribose)polymerase (PARP) inhibitor efficacious in BRCA-1 and -2 mutant tumors. J Med Chem 2009;52:7170–85
   PubMed Web of Science ®Google Scholar
• Penning TD, Zhu GD, Gandhi VB, et al. Discovery and SAR of 2-(1-propylpiperidin-4-yl)-1H-benzimidazole-4-carboxamide: a potent inhibitor of poly(ADP-ribose) polymerase (PARP) for the treatment of cancer. Bioorganic Med Chem 2008;16:6965–75
   PubMed Web of Science ®Google Scholar
• Ferraris D, Ficco RP, Pahutski T, et al. Design and synthesis of poly(ADP-ribose)polymerase-1 (PARP-1) inhibitors. Part 3: in vitro evaluation of 1,3,4,5-tetrahydro-benzo[c][1,6]- and [c][1,7]-naphthyridin-6-ones. Bioorganic Med Chem Lett 2003;13:2513–18
   PubMed Web of Science ®Google Scholar
• Ruf A, De Murcia G, Schulz GE. Inhibitor and NAD+ binding to poly(ADP-ribose) polymerase as derived from crystal structures and homology modeling. Biochemistry 1998;37:3893–900
   PubMed Web of Science ®Google Scholar
• Suto MJ, Turner WR, Arundel-Suto CM, et al. Dihydroisoquinolinones: the design and synthesis of a new series of potent inhibitors of poly(ADP-ribose) polymerase. Anticancer Drug Des 1991;6:107–17
   PubMedGoogle Scholar
• Frontini L, Lissoni P, Vaghi M, et al. Enhancement of the efficacy of weekly low-dose taxotere by the long acting anti-prolactinemic drug cabergoline in pretreated metastatic breast cancer. Anticancer Res 2004;24:4223–6
   PubMed Web of Science ®Google Scholar
• Howell SJ, Anderson E, Hunter T, et al. Prolactin receptor antagonism reduces the clonogenic capacity of breast cancer cells and potentiates doxorubicin and paclitaxel cytotoxicity. Breast Cancer Res 2008;10:R68
   PubMed Web of Science ®Google Scholar
• DeMichele A, Troxel AB, Berlin JA, et al. Impact of raloxifene or tamoxifen use on endometrial cancer risk: a population-based case-control study. J Clin Oncol 2008;26:4151–9
   PubMed Web of Science ®Google Scholar
• Lopez M, Di Lauro L, Papaldo P, et al. Phase II trial with oral idarubicin in advanced breast cancer. Invest New Drugs 1986;4:39–42
   PubMed Web of Science ®Google Scholar